Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2026-12-11
Target enrollment:
Participant gender:
Summary
This research is designed to determine if experimental treatment with AZD5863, a T
cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe,
tolerable and has anti-cancer activity in patients with advanced solid tumors.